ALBEMARLE CORP (ALB): M&A transaction — Albemarle completes sale of controlling Ketjen stake for ~$547M; launches $500M debt tender, redeems $650M notes

ALBEMARLE CORP

Sale to KPS Capital Partners: ~$547M cash ($22M included with Ketjen); combined with Eurecat sale totals ~$670M pre-tax.
Albemarle retains 49% minority stake in Ketjen; 100% of Performance Catalyst Solutions kept in-house.
Proceeds to fund debt reduction: cash tender offers up to $500M for 4 series of senior notes (2052, 2044, 2029, 2032).
Full redemption of $650M 4.650% Senior Notes due 2027 on March 12, 2026, plus accrued interest.
Tender offers expire March 30, 2026; early tender deadline March 13, 2026, with $50 per $1,000 premium.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ALBEMARLE CORP completed a disposition involving ChemCat AcquisitionCo, LLC for approximately $547 million in cash (closed 2026-03-02).

Action: disposition
Counterparty: ChemCat AcquisitionCo, LLC
Consideration: approximately $547 million in cash
Closing: 2026-03-02

Exact text from the filing

arrangements), and marketing catalysts and related products on a global basis. In connection with the Sale, Albemarle expects to receive an aggregate amount of approximately $547 million in cash, inclusive of $22 million in cash included with Ketjen at the time of the Sale. Together with the sale of its 50% interest in the Eurecat joint venture to Axens SA,

View on SEC.gov

Browse all m&a transactions →

ALBEMARLE CORP filing history →

Source: SEC EDGAR

accession 0000915913-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.